Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov;24(11):2916-22.
doi: 10.1093/annonc/mdt374. Epub 2013 Oct 7.

Advanced chondrosarcomas: role of chemotherapy and survival

A Italiano  1 , O Mir, A Cioffi, E Palmerini, S Piperno-Neumann, C Perrin, L Chaigneau, N Penel, F Duffaud, J E Kurtz, O Collard, F Bertucci, E Bompas, A Le Cesne, R G Maki, I Ray Coquard, J Y Blay
Affiliations

Advanced chondrosarcomas: role of chemotherapy and survival

A Italiano et al. Ann Oncol. 2013 Nov.

Abstract

Background: There are limited data about the role of chemotherapy in patients with advanced chondrosarcomas.

Methods: The medical charts of 180 patients with advanced chondrosarcomas having received chemotherapy in 15 participating institutions between 1988 and 2011 were reviewed.

Results: Median age was 52 years. Sixty-three percent of patients had conventional chondrosarcoma and 88% had metastatic disease. Combination chemotherapy was delivered in 98 cases (54.5%). One hundred and thirty-one patients (73%) received an anthracycline-containing regimen. Using RECIST, the objective response rate was significantly different according to histological subtype, being 31% for mesenchymal chondrosarcoma, 20.5% for dedifferentiated chondrosarcoma, 11.5% for conventional chondrosarcoma and 0% for clear-cell chondrosarcoma (P = 0.04). Median progression-free survival (PFS) was 4.7 months [95% confidence interval (CI) 3-6.5]. Performance status (PS) ≥2, number of metastatic sites ≥1 and single-agent regimen were independently associated with poor PFS. Median overall survival (OS) was 18 months (95% CI 14.5-21.6). PS, number of metastatic sites and palliative surgery were independently associated with OS.

Conclusions: Conventional chemotherapy have very limited efficacy in patients with advanced chondrosarcoma, the highest benefit being observed in mesenchymal and dedifferentiated chondrosarcoma. These data should be used as a reference for response and outcome in the assessment of investigational drugs in advanced chondrosarcoma.

Keywords: chemotherapy; chondrosarcoma; prognosis; treatment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Progression-free survival of the entire cohort of patients (A), and according to performance status (PS) (B), number of metastatic sites (C) and type of chemotherapy regimen (D).
Figure 2.
Figure 2.
Overall survival of the entire cohort of patients (A), and according to performance status (PS) (B), number of metastatic sites (C) and palliative surgery (D).
See this image and copyright information in PMC

References

    1. Fletcher CDM, Unni KK, Mertens F. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002. pp. 247–258.
    1. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977;40:818–831. - PubMed
    1. Mercuri M, Picci P, Campanacci L, et al. Dedifferentiated chondrosarcoma. Skeletal Radiol. 1995;24:409–416. - PubMed
    1. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–247. - PubMed
    1. van Oosterwijk JG, Herpers B, Meijer D, et al. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. Ann Oncol. 2012;23:1617–1626. - PubMed

Publication types

MeSH terms